Biotechnology News

2025 ANNUAL RESULTS Annual revenue up 9% to €168 millionRoll-out of the Group’s strategy: Sales of proprietary products up 20%, accounting for 35% of revenueInternationalisation: 42% of revenue...

RESULTAT ANNUEL 2025 Progression du chiffre d’affaires annuel de 9% à 168 M€Déploiement de la stratégie du Groupe : Ventes des produits propriétaires en hausse de 20%, à 35% du Chiffre...

NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that it has completed the acquisition of 100% of Zorronet...

Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28%...

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first...

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief...